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Abstract 
Background 
The aim was to examine the association between smoking cessation and prognosis in 
smoking-related cancer as it is unclear that cessation reduces mortality. 
 
Methods 
In this retrospective cohort study from 1999 to 2013, we assessed the association between 
cessation during the first year after diagnosis and all-cause and cancer-specific mortality.  
 
Results 
Of 2,882 lung, 757 upper aero-digestive tract and 1,733 bladder cancer patients 27%, 29% 
and 21% of lung, UAT and bladder cancer patients quit smoking.  In lung cancer patients that 
quit, all-cause mortality was significantly lower (HR 0.82 (0.74-0.92), while cancer-specific 
mortality (HR 0.89 (0.76-1.04) and death due to index cancer (HR 0.90 (0.77-1.05) were non-
significantly lower.  In UAT cancer, all-cause mortality (HR 0.81 (0.58-1.14), cancer-specific 
mortality (HR 0.84 (0.48-1.45), and death due to index cancer (HR 0.75 (0.42-1.34) were 
non-significantly lower.  There was no evidence of an association between quitting and 
mortality in bladder cancer.  The HRs were 1.02 (0.81-1.30) for all-cause, 1.23 (0.81-1.86) for 
cancer specific, and 1.25 (0.71-2.20) for death due to index cancer.  These showed a non-
significantly lower risk in sensitivity analyses. 
 
Conclusion 
People with lung and possibly UAT cancer who quit smoking have a lower risk of mortality 
than people who continue smoking.   
Key words: smoking, smoking cessation, cancer, primary care   
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Introduction 
Around a fifth of all cancers worldwide are caused by smoking, (Ezzati, 2005) and smoking-
related tumours commonly develop in the lung, upper aero-digestive tract (UAT) and 
bladder. (Thun, 2009) (US Surgeon General, 2014b)  Although five year survival rates for 
lung cancer are low, as most patients present in late stages,(Verdecchia, 2007, Walters, 
2013)  around 70% of patients who are treated curatively survive for 5 years.(UK., 2016)  
The proportion of people with curatively treated cancer is likely to increase with the advent 
of computerised tomography-based lung cancer screening. In upper aerodigetsive tract 
(UAT) and bladder cancer, the European mean age-standardised five-year survival rates are 
approximately 40% and 70%, respectively.(De Angelis, 2014)  Thus there is a large group of 
people with smoking-related cancer who may benefit from additional interventions to 
improve prognosis.  
 
There is some evidence that quitting smoking after diagnosis of smoking-related cancers 
may be associated with improved prognosis, particularly in patients who have been 
diagnosed in early stages.(Aveyard, 2002, Parsons, 2010, US Surgeon General, 2014b)  
However, many of these studies have methodological limitations such as a small sample size 
and unclear definitions of smoking status.(Gritz, 2014)  In addition, most studies compare 
the prognosis in patients who are smoking at diagnosis to those who have quit some time 
before or who have never smoked.  Few studies have focused on the prognostic benefit of 
quitting at or soon after diagnosis.(US Surgeon General, 2014b, Balough, 2014, Land, 2012) 
 
Many patients with smoking-related cancers are still smoking at diagnosis (Cooley, 2009, 
Park, 2012, Warren, 2013a) and support to quit is not routinely offered as part of cancer 
care. (Warren, 2013b, Murray, 2012) If quitting soon after diagnosis improved prognosis, 
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this would increase the clinical imperative to offer patients smoking cessation interventions 
to improve their chances of survival.  Unlike many treatments for cancer, smoking cessation 
treatment is safe and has mild adverse effects. In order to investigate if quitting after 
diagnosis has prognostic benefits, we estimated the association between quitting and all-
cause mortality in lung, UAT and bladder cancer patients using a large dataset of routinely-
collected primary care data.  Cessation reduces mortality from cardiorespiratory disease and 
thus cessation would be expected to reduce mortality from this cause.  We therefore 
investigated whether some of the benefit could be due to prevention of cancer progression 
by examining the association between quitting and death due to cancer. 
 
Methods 
We conducted a retrospective cohort study using routinely-collected UK primary care 
records from the Clinical Practice Research Datalink (CPRD) (www.cprd.com).  The protocol 
was approved by the Independent Scientific Advisory Committee (ISAC) for MHRA database 
research (ref no: 14_105), and was made available during the peer review process. Patients 
with a first diagnosis of lung, UAT and bladder cancers between 1999 and 2013 who smoked 
at diagnosis, survived for one year, had been registered with a practice for at least one year 
and had at least one year of follow-up data were included in the cohort. UAT cancers mainly 
included cancers that occur in the mouth and throat and full definitions and the Read codes 
used for each cancer are provided in Appendix 1. (HSCIC, 2014) We restricted the analysis to 
patients that survived for at least one year to limit confounding by stage of cancer at 
diagnosis.  Stage was not recorded in most cases.  People with advanced cancer treated 
palliatively may be less likely to stop smoking and are more likely to die, thus confounding 
the association between smoking cessation and mortality. As many such patients die within 
a year, restricting the analysis in this way limited confounding. Patients were followed up 
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until the end of 2013 or death, or were censored if they moved practice. In 2013, the CPRD 
database contained records from 4.4 million live patients in 674 practices, which 
represented 6.9% of the UK population.(Herrett, 2015)  The first version of the protocol was 
amended to exclude people with thyroid cancer because this is not a smoking-related head 
and neck cancer.  
 
Patients were defined as smokers at diagnosis if they were recorded as smoking on the last 
occasion smoking status was updated within the three years prior to diagnosis.  People were 
classified as having stopped smoking or continued smoking during the first year of follow-up 
if their last record during that period recorded either state.  Some people did not have their 
smoking status updated after diagnosis and we conducted sensitivity analyses to examine 
the impact of this on the findings.   
 
Survival time was calculated as the time from the end of the first year after diagnosis until 
outcome occurrence (all-cause mortality, cancer specific mortality or death due to index 
cancer).  The fact of death was taken from the CPRD record and also from the UK national 
system of recording death provided by the Office for National Statistics (ONS) and this was 
used for all-cause mortality analyses.  The CPRD database does not record cause of death 
but ONS does.  Thus, for those patients in practices where ONS death data could be linked, 
we examined cancer specific mortality and death due to index cancer. To do so, ONS data 
were linked to each person’s CPRD data.  In the protocol, we planned to investigate 
development of a recurrence or development of a second primary tumour but were unable 
to do this as these outcomes were poorly recorded.   
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Survival curves were generated with the Kaplan Meier plot method for each outcome. We 
used Cox proportional hazard regression models to compare differences in survival between 
people who stopped and people who continued smoking in each cancer group. The 
proportional hazards assumption was examined by the use of log-log plots and Schoenfeld 
residuals.  The results are presented as hazard ratios with 95% confidence intervals and we 
use the term non-significant as shorthand to mean that the 95% confidence intervals 
included unity. In the main analyses, we adjusted for age, gender, socio-economic status 
(SES), comorbidity (asthma, chronic kidney disease (CKD), chronic obstructive pulmonary 
disease (COPD), diabetes, hypertension, peripheral arterial disease (PAD), stroke, 
psychoses), treatment and alcohol consumption.  Patients whose smoking status after 
diagnosis was missing were included as an additional exposure category. Due to missing 
data on smoking status after diagnosis, alcohol status and SES we used multiple imputation 
(MI) models to impute these data. We used the mi command in STATA 14 with 20 imputed 
datasets, including the baseline and clinical characteristics, outcome and the Nelson-Aalen 
estimator of the cumulative hazard function.(White, 2009)   
 
Sensitivity analyses were conducted to investigate the robustness of MI models. Sensitivity 
analyses comprised unadjusted analysis, full case analysis and full case analysis where 
patients that did not have their smoking status updated within the year following diagnosis 
were classified as continued smokers.  We performed two additional sensitivity analyses but 
do not show the data as the results of these analyses were very similar to the main results.  
First, we excluded covariates with missing data (alcohol status and SES).  Second, in 
response to a referee, we adjusted for year of diagnosis, which made no material difference, 
and then added a multiplicative interaction term between smoking status and year of 
diagnosis and this was not significant in any analysis.  
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Results 
During the study period, there were a total of 42,112 incident cancer cases (lung n=27,615, 
UAT n=3,248, bladder n=11,249).  Information regarding smoking status at diagnosis was 
available for 81% of these cases (lung 83%, UAT 78%, bladder 79%), and we assumed that 
patients with missing status were either never smokers, or long-term ex-smokers, consistent 
with the rules GPs for updating smoking status.(Marston, 2014)  Based on this assumption, 
36%, 35% and 20% of lung, UAT and bladder cancer patients were smoking at diagnosis. We 
included in our analyses patients who smoked at diagnosis and who had survived for at least 
one year.  This included 2,882 people with lung cancer (27% quit, 39% continued, 34% 
unknown), 757 people with UAT cancer (29% quit, 37% continued, 34% unknown) and 1,733 
people with bladder cancer (21% quit, 49% continued, 30% unknown).  As not every practice 
in the CPRD database is linked to ONS for the cause of death analyses, the cohorts for the 
analyses of cancer-specific mortality and death due to index cancer were smaller (lung 
cancer n=1,635; UAT cancer n=428; bladder cancer n=1,013) (Figure 1). 
 
The baseline demographic characteristics were similar across smoking exposure groups (quit 
during first year, continued during first year, no smoking update during first year) for each 
cancer group.  There were some imbalances in the presence of comorbidities across 
exposure groups for each cancer group (Table 1).  A higher proportion of patients who quit 
smoking received surgery.  However, these baseline characteristics were controlled for in 
the analyses.  
 
Association between smoking status after diagnosis and all-cause mortality 
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Lung cancer patients who quit smoking had a significantly lower risk of all-cause mortality 
compared with patients who continued to smoke (unadjusted HR 0.71 (95% CI 0.63-0.79), 
adjusted HR 0.82 (95% CI 0.74-0.92)) (Table 2). Median survival (from one year after 
diagnosis) for patients who continued smoking was 1.08 years (95%CI 0.94-1.24), and was 
1.97 years (1.68-2.26) for patients who quit.  In UAT, quitting smoking was associated with a 
non-significantly lower risk of mortality which was unchanged after adjustment (unadjusted 
HR 0.80 (0.60-1.08), adjusted HR 0.81 (0.58-1.14)). There was no evidence of an association 
between quitting and mortality in patients with bladder cancer (unadjusted HR 0.91 (95% CI 
0.73-1.14), adjusted HR 1.02 (0.81-1.30)) (Figure 2). The sensitivity analysis with different 
assumptions produced very similar results to these for all cancers (Table 2).  
 
Association between smoking status after diagnosis and cancer-specific mortality  
Eighty-six percent of deaths in patients with lung cancer were due to cancer.  Quitting 
smoking after a diagnosis of lung cancer was associated with lower cancer-specific mortality 
(unadjusted HR 0.73 (0.62-0.85)), but this became non-significant after adjustment (HR 0.89 
(0.76-1.04)) (Table 2). Less than two thirds of the deaths after UAT and bladder cancer were 
due to cancer (65% and 59% respectively).  Quitting smoking after diagnosis of either cancer 
was not significantly associated with reduced cancer-specific mortality (Table 2, Figure 3).  
Sensitivity analysis again showed very similar results.   
 
Association between smoking status after diagnosis and death due to index cancer 
There was no significant association between quitting smoking and death due to index 
cancer in lung (unadjusted HR 0.72 (0.61-0.85), adjusted HR 0.90 (0.77-1.05, UAT 
(unadjusted HR 0.78 (0.45-1.37), adjusted HR 0.75 (0.42-1.34) or bladder cancer patients 
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(unadjusted HR 1.24 (0.77-1.99), adjusted HR 1.25 (0.71-2.20)) (Table 2, Figure 4). Sensitivity 
analysis produced similar results for lung and UAT cancers but there was a modest 
difference between the multiple imputation and the full case models for bladder cancer. 
However, neither set of models suggested a significant increase or decrease in risk for 
people who stopped smoking.  
 
Discussion 
A third of patients with lung and UAT cancer and a fifth of those with bladder cancer 
smoked at diagnosis, and the majority continued after their diagnosis.  In patients who 
survived for at least one year, smoking cessation during that first year was associated with a 
lower risk of all-cause mortality in lung cancer and the evidence was suggestive of a lower 
risk in UAT cancer.  There was inconclusive evidence that quitting was associated with 
survival in bladder cancer. There was inconclusive evidence that smoking cessation was 
associated with lower mortality in each cancer type. 
 
This study included many more people than previous studies investigating the impact of 
smoking cessation on survival, therefore producing more precise estimates of association.  
However, there were fewer people with data available on cause of death.  This meant that 
the estimates for cancer-specific outcomes were less precise and it was not possible to be 
sure whether the apparent survival benefit arose from reduced deaths from cardiac and 
respiratory causes or from reduced deaths due to cancer in UAT cancer because the 
confidence intervals for cancer-specific deaths were wider.  However, for lung cancer, it 
appears clearer that quitting smoking is associated with a lower cancer-specific mortality, 
mainly because the large majority of deaths were due to lung cancer, although the adjusted 
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estimates of cancer-specific mortality (based on a subsample) were not themselves 
significant. 
 
This study has some limitations.  Firstly, smoking status was taken from the medical records 
and these may not accurately record true smoking status.  Doctors did not record whether 
around a third of people continued or stopped smoking, though sensitivity analysis suggest 
the results were insensitive to this.  Some people who were recorded as having stopped 
smoking may have subsequently relapsed while some recorded as continuing may 
subsequently stopped. This mixing of exposure assignment is likely to underestimate the 
strength of association, (Sorahan and Gilthorpe, 1994, Wacholder et al., 1995) but it creates 
uncertainty. Although we controlled for a range of confounders, we were unable to adjust 
for all possible confounders.  In particular, data on stage at diagnosis is not recorded in UK 
primary care notes so this could not be controlled for in the analysis.  There is no biologically 
plausible reason why those who quit smoking after diagnosis would present with more 
favourable stage than those who continued to smoke.  However, it is plausible that 
presenting with more advanced cancer undermines motivation to stop smoking and that 
this would confound the association, producing the associations in the direction we 
observed.  In addition, primary care records have limited information on the treatment 
received and often this was not recorded.  Consequently, it was not possible to reliably 
differentiate those treated curatively from those treated palliatively.  We confined the 
analysis to people who survived at least a year to try to limit this confounding, but this may 
not have been entirely successful.  In addition, SES and alcohol consumption were not well 
recorded, and more than 20% of people had missing data for these variables so we used 
multiple imputation models.  These models produced broadly similar results to the models 
that did not control for these variables.  
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Interpretation and context with previous literature 
Our findings relating to all-cause mortality are consistent with other published 
literature.(Parsons, 2010, Aveyard, 2002, Mayne, 2009, Browman, 1993, Clark, 2006)  We 
have previously reported a systematic review of studies in lung cancer patients that found 
that, after adjustment for key prognostic factors, quitting was associated with reduced 
mortality, with a HR of 0.34 (95%CI 0.13-0.87) for non-small cell cancer and 0.54 (95%CI 
0.39-0.75) for small cell lung cancer.(Parsons, 2010)  Both these estimates were derived 
from only one study each, with around 200 participants.  Our study produced more modest 
estimates of the benefits of quitting in lung cancer, but the point estimates are within these 
confidence intervals.  Similarly, studies comparing mortality between people who quit 
smoking after diagnosis of head and neck cancer and people who continue to smoke have 
found lower mortality risk in those who quit.  For example, Mayne et al 2009 reported a 
significantly lower risk of mortality (HR 0.30 95%CI 0.16-0.57)(Mayne, 2009) and Browman 
et al reported improved two-year survival (66% versus 39%, p=0.005).(Browman, 1993)  
Studies in patients with bladder cancer have compared rates of all-cause mortality in people 
who smoke at diagnosis to those who have never smoked, or to those who have quit some 
time before diagnosis, but not to people who quit after diagnosis and therefore there is no 
evidence from previous studies to compare our results with.(Aveyard, 2002, Van Osch, 
2016)  In our analysis we adjusted for common comorbidities, and smoking cessation was 
still associated with a risk of death due from any cause in lung cancer. There is strong 
evidence elsewhere that quitting smoking reduces the risk of heart disease and respiratory 
death,(Critchley, 2003) including from a clinical trial (Anthonisen, 2002) and therefore we 
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conclude that the association between quitting and reduced all-cause mortality in lung 
cancer is causal. 
 
There is evidence that continued smoking increases risk of a second primary cancer and  
recurrence, (US Surgeon General, 2014a)but the evidence that quitting at the time of 
diagnosis reduces this risk is relatively weak.  For example, in our review of lung cancer 
patients, both non-small cell and small cell lung cancer patients who quit smoking had a 
lower risk of recurrence (NSCLC HR 0.54 (0.29-0.99); SCLC HR 0.79 (0.67-0.94) and small cell 
lung cancer patients had a lower risk of second primary tumour although confidence 
intervals were wide (HR 0.23 (0.05-0.92).(Parsons, 2010)  Each of these estimates originate 
from one study only which include a small numbers of patients.(Nia, 2005, Kawahara, 1998, 
Videtic, 2003)  Do et al found that in patients with early stage head and neck squamous cell 
carcinoma, continued smokers and quitters were both more likely to develop second 
primary tumours than never smokers.  However, when indirectly comparing continuing 
smokers and quitters,(Bucher, 1997) there was no evidence of a difference in risk (HR 0.94 
(95%CI 0.34-2.60).[Do, 2004] Leon et al. conducted a matched case control study in patients 
with head and neck cancer and found that quitters had a significantly lower risk of a second 
primary neoplasm compared with those who continued to smoke (HR 0.34 (95%CI 0.24-
0.56)).(Leon, 2009) In patients with superficial transitional cell carcinoma of the bladder, 
Fleshner et al reported data that allowed us to compare the risk of recurrence in patients 
who quit smoking after diagnosis to those who continued to smoke.(Fleshner, 1999)  
Indirect comparison showed quitters were at lower risk of recurrence, but it was not 
significant (HR 0.71 (0.48-1.05)).(Aveyard, 2002) Taken together with our findings, the 
evidence appears inconclusive that quitting smoking lowers the risk of cancer progression in 
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people with bladder cancer.  However, overall there is stronger evidence that quitting 
improves cancer outcomes in UAT and lung cancer.  
 
There are several potential mechanisms by which continued smoking may affect cancer-
specific survival.  Previous studies have shown that continued smoking may reduce the 
effectiveness of adjuvant cancer treatment.(Zevallos, 2009, Gajdos, 2012, Chen, 2011, 
Dresler, 2003, Gritz, 2005)  For example, tobacco smoke reduces plasma concentrations of 
chemotherapeutic agents as it is a potent inducer of the cytochrome P450 enzymes which 
metabolise several drugs in the liver, including some chemotherapies.(Petros, 2012, Dresler, 
2003)  In addition to affecting treatment, constituents of tobacco smoke may also alter the 
behaviour of cancer cells or aid processes that support tumour development and 
progression.(Yoshino, 2007, Warren, 2014)  Cigarette smoke contains many potential 
irritants and is a strong inflammatory stimulus,(Lee, 2012, Warren, 2014) and evidence is 
been mounting that an inflammatory microenvironment aids development and progression 
of tumours.(Balkwill, 2001, Mantovani, 2008, Lee, 2012, Aggarwal, 2006)  It is possible that 
these mechanisms may be at play in the increased risk of death associated with continued 
smoking in lung and UAT cancers.  
 
These results reinforce the need to provide active and ongoing smoking cessation support 
for people with cancer who smoke which is both a non-toxic and cost-saving intervention 
for the patient.  In addition to reduced survival, previous studies have shown that continued 
smoking is associated with lower quality of life (Garces, 2014) increased pain,(Daniel, 2009) 
treatment-related toxicity(Gritz, 2014, US Surgeon General, 2014b) and longer length of 
hospital stay in cancer patients .(Erhunmwunsee, 2009)  Many patients try to quit on 
diagnosis,(Gritz, 1991) so those who relapse find themselves involuntarily trapped by their 
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addiction.  The lesson of the Lung Health Study, a study of people who continued smoking 
despite COPD, is that continued support for smoking cessation, despite early failure to quit, 
improves outcomes for patients.(Scanlon, 2000)  There is strong evidence that smoking 
cessation support in hospitalised patients that continues for at least a month after discharge 
increases rates of cessation.(Rigotti, 2012)  English (NICE) guidance recommends that 
patients accessing secondary care should be offered support to quit smoking within this 
setting, and for inpatients, this should include referral to intensive smoking cessation 
support which continues after discharge.(Excellence., 2013)  Despite this, support for 
smoking cessation is not well integrated into cancer care(Murray, 2012, Warren, 2013b) and 
future work should examine interventions to improve the health system to provide 
treatment for tobacco dependence.   
 
Conclusion 
Most lung, UAT and bladder cancer patients who smoke at diagnosis continue smoking.  
However, quitting smoking reduces the risk of death in lung cancer and may do so in UAT 
cancer, but there is no evidence in this study that it does so in bladder cancer.  The 
reduction in risk of death may be due to a decreased risk of cancer progression, but this 
needs further investigation. 
 
Funding 
This work was supported by the NIHR School for Primary Care Research (project number: 
224).  The funder was not involved in the design and conduct of the study; collection, 
management, analysis, and interpretation of the data; or preparation, review, or approval of 
the manuscript. 
 
15 
 
Acknowledgements 
This study has been presented as an oral presentation at the UK Nicotine and Smoking 
Cessation Conference, London, June 2016. 
Seven authors have contributed to this study: Amanda Farley PhD, Constantinos Koshiaris 
MSc, Jason Oke DPhil, Ronan Ryan PhD, Lisa Szatkowski PhD, Richard Stevens PhD, and Paul 
Aveyard PhD. All authors developed and approved the study protocol.  CK, JO and RS 
conducted or supervised the data processing and analysis.  Drafting of the manuscript was 
led by AF, and contributed to by all authors.  All authors have approved the final version of 
the manuscript. 
Three of our authors report potential conflicts of interest, and the remaining four do not 
have any to report.  The potential conflicts are as follows: 
Paul Aveyard reports grants from MRC, NIHR, CRUK, ESRC, and UK Centre for Tobacco and 
Alcohol Studies during the conduct of this study; Amanda Farley reports grants from the 
NIHR and CRUK during the conduct of this study; Ronan Ryan reports that he was part-
funded by the National Health Service (Heart of England NHS Foundation Trust) during the 
conduct of this study. 
  
16 
 
 
References 
AGGARWAL, B., SHISHODIA, S., SANDUR, SK., PANDEY, MK., SETHI, G. 2006. Inflammation and 
cancer: How hot is the link?  . Biochemical pharmacology, 72, 1605-1621. 
ANTHONISEN, N., CONNETT, JE., ENRIGHT, PL., MANFREDA, J.,  FOR THE LUNG HEALTH STUDY 
RESEARCH GROUP. 2002. Hospitalizations and mortality in the Lung Health Study American 
Journal of Respiratory Critical Care Medicine 166, 333-9. 
AVEYARD, P., ADAB, P., CHENG, KK., WALLACE, DM., HEY, K., MURPHY, MF. 2002. Does smoking 
status influence the prognosis of bladder cancer? A systematic review. . BJU International 
90, 228-239. 
BALKWILL, F., MANTOVANI, A. 2001. Inflammation and cancer: back to Virchow? . Lancet, 357, 539-
545. 
BALOUGH, E., DRESLER, C., FLEURY, ME., GRITZ, ER., KEAN, TJ., MYERS, ML., NASS, SJ., NEVIDJON, B., 
TOLL, BA., WARREN, GW., HERBST, RS 2014. Reducing tobacco-related cancer incidence and 
mortality: summary of an institute of medicine workshop  The Oncologist, 19, 21-31. 
BROWMAN, G., WONG, G., HODSON, I., SATHYA, J., RUSSELL, R., MCALPINE, L., SKINGLEY, P., LEVINE, 
MN. 1993. Influence of cigarette smoking on the efficacy of radiation therapy in head and 
neck cancer New England Journal of Medicine, 328, 159-163. 
BUCHER, H., GUYATT, GH., GRIFFITH, LE., WALTER, SD. 1997. The results of direct and indirect 
treatment comparisions in meta-anlaysis of randomized controlled trials. . J Clin 
Epidemiology, 50, 683-691. 
CHEN, A., CHEN, LM., VAUGHAN, A., SREERAMAN, R., FARWELL, DG., LUU, Q., LAU, DH., STUART, K., 
PURDY, JA., VIJAYAKUMAR, S. 2011. Tobacco smoking during radiation therapy for head and 
neck cancer is associated with unfavourable outcome  Int J Rad Oncol Biol Phys, 79, 414-9. 
CLARK, T., MURPHY, MF., HAY, K., DRURY, M., CHENG, KK., AVEYARD, P. 2006. Does smoking 
influence survival in cancer patients through effects on respiratory and vascular disease?  . 
European Journal of Cancer Prevention, 15, 87-90. 
COOLEY, M., SARNA, L., KOTLERMAN, J., LUKANICH, JM., JAKLITSCH, M., GREEN, SB., BUEON, R. 
2009. Smoking cessation is challenging even for patients recovering from lung cancer surgery 
with curative intent. Lung Cancer, 66, 218-25. 
CRITCHLEY, J., CAPEWELL, S. 2003. Mortality risk reduction associated with smoking cessation in 
patients with coronary heart disease: a systematic review JAMA, 290, 86-97. 
DANIEL, M., KEEFE, FJ., LYNA, P., PETERSON, B., GARST, J., KELLEY, M., BELPER, G., BASTIAN, LA. 
2009. Persistent smoking after a diagnosis of lung cancer is associated with higher reported 
pain levels  J Pain, 10, 323-328. 
DE ANGELIS, R., SANT, M., COLEMAN, MP., FANCISCI, S., BAILI, P., PIERANNUNZIO, D., TRAMA, A., 
VISSER, O., BRENNER, H., ARDANAZ, E., BIELSKA-LASOTA, M., ENGHOLM, G., NENNECKE, A., 
SIESLING, S., BERRINO, F., CAPOCACCIA, R., EUROCARE-5 WORKING GROUP.    2014. Cancer 
Survival in Europe 1999-2007 by country and age: results of EUROCARE-5 – a population-
based study. Lancet Oncology, 15, 23-34. 
DRESLER, C. 2003. Is it more important to quit smoking than which chemotherapy is used? Lung 
cancer, 39, 119-124. 
ERHUNMWUNSEE, L., ONAITIS, M. 2009. Smoking cessation and the success of lung cancer surgery.  . 
Curr Oncol Rep, 11, 269-274. 
EXCELLENCE., N. I. F. H. A. C. 2013. NICE guidelines [PH48] Smoking: acute, maternity and mental 
health services. 
EZZATI, M., HENLEY, SJ., LOPEZ, AD., TUN, MJ. 2005. Role of smoking in global and regional cancer 
epidemiology: current patterns and data needs. Int. J. Cancer,, 116, 963-971. 
17 
 
FLESHNER, N., GARLAND, J., MOADEL, A., HERR, H., OSTROFF, J., TRAMBERT, R., O'SULLIVAN, M., 
RUSSO, P. 1999. Influence of smoking status on the disease-related outcomes of patients 
with tobacco-associated superficial transitional cell carcinoma of the bladder. . Cancer., 86, 
2337-45. 
GAJDOS, C., HAWN, MT., CAMPAGNA, EJ., HENDERSON, WG., SINGH, JA., HOUSTON, T. 2012. 
Adverse effects of smoking on postoperative outcomes in cancer patients  Annals of Surgical 
Oncology, 19, 1430-8. 
GARCES, Y., YANG, P., PARKINSON, J., ZHAO, X., WAMPFLER, JA., EBBERT, JO., SLOAN, JA. 2014. The 
relationship between cigarette smoking and quality of life after lung cancer diagnosis  CHEST 
Journal, 126, 1733-1741. 
GRITZ, E., DRESLER, C., SARNA, L. 2005. Smoking, the missing drug interaction in clinical trials: 
ignoring the obvious.  . Cancer epidemiology, biomarkers and prevention, 14, 2287-2293. 
GRITZ, E., NISENBAUM, R., ELASHOFF, RE., HOLMES EC. 1991. Smoking behavior following diagnosis 
in patients with stage I non-small cell lung cancer. Cancer Causes and Control, 2, 105-112. 
GRITZ, E., TOLL, BA., WARREN, GW. 2014. Tobacco use in the oncology setting: advancing clinical 
practice and research  Cancer Epidemiology, Biomarkers & Prevention, 23, 3-9. 
HERRETT, E., GALLAGHER, AM., BHASKARAN, K., FORBES, H., MATHUR, R., VAN STAA, T., SMEETH, L. 
2015. Data Resource Profile: Clinical Practice Research Datalink (CPRD). International Journal 
of Epidemiology, dyv098–. doi:10.1093/ije/dyv098. 
HSCIC. 2014. Available: 
https://isd.hscic.gov.uk/trud3/user/guest/group/0/pack/9/subpack/8/releases [Accessed, 
2014] [Accessed]. 
KAWAHARA, M., USHIJIMA, S., KAMIMORI, T., KODAMA, N., OGAWARA, M., MATSUI, K., TAKADA, 
M., SOBUE, T., FURUSE, K. 1998. Second primary tumors in more than 2 year diseasefree 
survivors of small cell lung cancer in Japan: the role of smoking cessation Br J Cancer, 78. 
LAND, S. 2012. Methodologic barriers to addressing critical questions about tobacco and cancer 
prognosis  Journal of clinical oncology, 30, 2030-2032. 
LEE, J., TANEJA, V., VASSALLO. 2012. Cigarette smoking and inflammation  J Dent Res, 91, 142-149. 
LEON, X., DEL PRADO VENEGAS, M., ORUS, C., LOPEZ, M., GARCIA, J., QUER, M. 2009. Influence of 
the persistence of tobacco and alcohol use in the appearance of second neoplasm in 
patients with a head and neck cancer. A case-control study.  . Cancer Causes and Control, 20, 
645-52. 
MANTOVANI, A., ALLAVENA, P., SICA, A., BALKWILL, F. 2008. Cancer-related inflammation. . Nature, 
454, 436-444. 
MARSTON, L., CARPENTER, JR., WALTERS, KR., MORRIS, RW., NAZARETH, I., WHITE, IR., PETERSEN, I. 
2014. Smoker, ex-smoker or non-smoker? The validity of routinely recorded smoking status 
in UK primary care: a cross-sectional study. BMJ Open, 4:e004958. 
MAYNE, S., CARTMEL, B., KIRSH, V., GOODWIN, WJ JR. 2009. Alcohol and tobacco use prediagnosis 
and postdiagnosis, and survival in a cohort of patients with early stage cancers of the oral 
cavity, pharynx, and larynx.  . Cancer epidemiology, biomarkers and prevention, 18, 3368-74. 
MURRAY, R., LEONARDI-BEE, J., MARSH, J., JAYES, L., BRITTON, J. 2012. Smoking status 
ascertainment and interventions in acute medical patients.  . Clin Med, 12. 
NIA, P., WEYLER, J., COLPAERT, C., VERMEULEN, P., MARCK, EV., CHIL, PV. 2005. Prognostic value of 
smoking status in operated non-small cell lung cancer.  . Lung cancer, 47, 351-9. 
PARK, E., JAPUNTICH, SJ., RIGOTTI, NA., TRAEGER, L., HE, Y., WALLACE, RB., MALIN, JL., ZALLEN, JP., 
KEATING, NL. 2012. A snapshot of smokers after lung and colorectal cancer diagnosis. . 
Cancer, 118, 3153-64. 
PARSONS, A., DALEY, A., BEGH, R., AVEYARD, P. 2010. Influence of smoking cessation after diagnosis 
of early stage lung cancer on prognosis: systematic review of observational studies with 
meta-analysis. . BMJ 340. 
PETROS, W., YOUNIS, IR., FORD, JN., WEED, SA. 2012. Effects of tobacco smoking and nicotine on 
cancer treatment  Pharmacotherapy, 32. 
18 
 
RIGOTTI, N., MUNAFO, MR., STEAD, LF. 2012. Interventions for smoking cessation in hospitalised 
patients.   . Cochrane Database Syst Rev, May 16;5: . 
SCANLON, P., CONNETT, JE., WALLER, LA.,  ALTOSE, MD., BAILEY, WC., BUIST, AS., TASHKIN, DP., FOR 
THE LUNG HEALTH STUDY RESEARCH GROUP.  2000. Smoking cessation and lung function in 
mild-to-moderate chronic obstructive pulmonary disease American Journal of Respiratory 
and Critical Care Medicine, 161, 381-390. 
SORAHAN, T. & GILTHORPE, M. S. 1994. Non-differential misclassification of exposure always leads 
to an underestimate of risk: an incorrect conclusion. Occup Environ Med, 51, 839-40. 
THUN, M., DELANCEY, JO., CENTER, MM., JEMAL, A., WARD, EM. 2009. The global burden of cancer: 
priorities for prevention Carcinogenesis 31, 100-110. 
UK., C. R. 2016. Lung cancer survival statistics [Online]. Available: 
http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-
type/lung-cancer/survival#heading-Zero [accessed 09/02/2016] [Accessed]. 
US SURGEON GENERAL 2014a. The Health Consequences of Smoking—50 Years of Progress: A 
Report of the Surgeon General. US Department of Health and Human Services. 
US SURGEON GENERAL 2014b. The health consequences of tobacco smoke- 50 years on: a report of 
the surgeon general http://www.surgeongeneral.gov/library/reports/50-years-of-progress/. 
VAN OSCH, F., JOCHEMS, SHJ., VAN SCHOOTEN, FJ., BRYAN, RT., ZEEGERS, MP. 2016. Significant role 
of lifetime cigarette smoking in worsening bladder cancer and upper tract urothelial 
carcinoma prognosis: A Meta-Analysis. Journal of Urology, 195, 1-8. 
VERDECCHIA, A., FRANCISCI, S., BRENNER, H., GATTA, G., MICHELI, A., MANGONE, L., KUNKLER, I., 
EUROCARE-4 WORKING GROUP. 2007. Recent cancer survival in Europe: a 2000-02 period 
analysis of EUROCARE-4 data Lancet Oncology 8, 784-96. 
VIDETIC, G., STITT, LW., DAR, AR., KOCHA, WI., TOMIAK, AT., TRUONG, PT., VINCENT, MD., YU, EW. 
2003. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for 
limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 21, 
1544-9. 
WACHOLDER, S., HARTGE, P., LUBIN, J. H. & DOSEMECI, M. 1995. Non-differential misclassification 
and bias towards the null: a clarification. Occup Environ Med, 52, 557-8. 
WALTERS, S., MARINGE, C., COLEMAN, MP., PEAKE, MD., BUTLER, J., YOUNG, N., BERGSTROM, S., 
HANNA, L., JAKOBSEN, E., KOLBECK, K., SUNDROM, S., ENGHOLM, G., GAVIN, A., 
GJERSTORFF, ML., HATCHER, J., JOHANNESEN, TB., LINKLATER, KM., MCGAHAN, CE., 
STEWARD, J., TRACEY, E., TURNER, D., RICHARDS, MA., RACHET, B., ICBP MODULE 1 
WORKING GROUP. 2013. Lung cancer survival and stage at diagnosis in Australia, Canada, 
Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007 Thorax, 68, 
551-64. 
WARREN, G., KASZA, KA., REID, ME., CUMMINGS, M., MARSHALL, JR. 2013a. Smoking at diagnosis 
and survival in cancer patients International Journal of Cancer 132, 401-410. 
WARREN, G., MARSHALL, JR., CUMMINGS, KM., TOLL, BA., GRITZ, ER., HUTSON, A., DIBAJ, S., 
HERBST, R., MULSHINE, JL., HANNA, N., DRESLER, CA. 2013b. Addressing tobacco use in 
patients with cancer: a survey of American society of clinical oncology member.  . J Oncol 
Pract., 9, 258-62. 
WARREN, G., SOBUS, S., GRITZ, E. 2014. The biological and clinical effects of smoking by patients 
with cancer and strategies to implement evidence-based tobacco cessation support  Lancet 
Oncology, 15. 
WHITE, I., ROYSTON, P. 2009. Imputing missing covariate values for the Cox model. . Statistics in 
medicine, 28, 1982-1998. 
YOSHINO, I., MAEHARA, Y.  2007. Impact of smoking status on the biological behavior of lung cancer. 
Surgery Today 37, 725-734. 
ZEVALLOS, J., MALLEN, MJ., LAM, CY., KARAM-HAGE, M., BLALOCK, J., WETTER, DW., GARDEN, AS., 
STURGIS, EM., CINCIRIPINI, PM. 2009. Complications of radiotherapy in laryngopharyngeal 
cancer: effects of a prospective smoking cessation program  Cancer, 115, 4636-44. 
19 
 
Figure 1 Flow of participants through the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Unadjusted risk of all-cause mortality in patients who quit smoking compared with 
those who continued to smoke after diagnosis 
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Figure 3 Unadjusted risk of cancer specific mortality in patients who quit smoking compared 
with those who continued to smoke after diagnosis 
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Figure 4 Unadjusted risk of death due to index cancer in patients who quit smoking 
compared with those who continued to smoke after diagnosis 
(a) Lung cancer  
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Table 1: Baseline characteristics of patients with lung, bladder and upper aero-digestive tract cancer by smoking exposure status 
Characteristics Lung cancer Upper aero-digestive tract (UAT) cancer Bladder cancer 
Continued 
smoking  
(N=1129, 
39%) 
Quit smoking 
(N=784, 27%) 
Status not 
updated 
(N=969, 34%) 
Continued 
smoking  
(N=281, 37%) 
Quit smoking  
(N=216, 29%) 
Status not 
updated 
(N=260,  
34%)  
Continued 
smoking  
(N=850,  
49%) 
Quit smoking 
(N=356, 21%) 
Status not 
updated 
(N=527, 30%)  
Gender (%male)  588  
(52.1%) 
364 (46.4%)  484  
(49.9%) 
197 (70.1%) 143  
(66.2%) 
181  
(69.6%) 
618  
(72.7%) 
269 (75.6%) 418 (79.3%) 
Age (mean, SD yrs) 67.1  
(9.97) 
66.3 (9.04) 65.8  
(10.4) 
59.65 (10.86) 61 
(10.83) 
59.96  
(11.2) 
67.49 
 (10.7) 
65.39 (10.8) 66.14 (11.5) 
Patients with ONS linkage 625  
(55.4%) 
466 (59.4%) 544 
 (56.1%) 
154 (54.8%) 120  
(55.6%) 
154  
(59.2%) 
494 
 (58.1%) 
207 (58.15%) 312 (59.2%) 
Alcohol status           
Non drinkers 264  
(23.4%) 
180 (22.9%) 216 
 (22.3%) 
36  
(12.8%) 
35  
(16.2%) 
38 
 (14.6%) 
228  
(26.8%) 
96  
(27%) 
126 (23.9%) 
Ex-drinkers 103 
 (9.1%) 
54 (6.9%) 49  
(5%) 
22 
 (7.8%) 
13 
 (6%) 
9 
 (3.5%) 
85  
(10%) 
22 (6.2%) 20  
(3.8%) 
Light drinkers 101 
 (9%) 
55  
(7%) 
75 
 (7.7%) 
18 
 (6.4%) 
25  
(11.6%) 
24  
(9.2%) 
65 
 (7.7%) 
35 (9.8%) 55  
(10.4%) 
Moderate drinkers 100  
(8.9%) 
63  
(8%) 
65  
(6.7%) 
39 
 (13.9%) 
29 
 (13.4%) 
37 (14.2%) 79  
(9.3%) 
29 (8.2%) 38  
(7.2%) 
Heavy drinkers 30  
(2.7%) 
10 (1.3%) 20  
(2.1%) 
26 
 (9.3%) 
11 
(5.1%) 
16  
(6.2%) 
16 
 (1.9%) 
4  
(1.1%) 
8 
 (1.5%) 
Drinkers (unknown amount) 60 
 (5.3%) 
30 (3.8%) 25  
(2.6%) 
18 
 (6.4%) 
8  
(3.7%) 
13 
 (5%) 
28 
 (3.3%) 
25 
 (7%) 
8  
(1.5%) 
No record found 471 
 (41.7%) 
392 (50%) 519  
(53.6%) 
122 (43.4%) 95  
(43.8%) 
123  
(47.3%) 
349 
 (41.1%) 
145 (40.7%) 272 (51.6%) 
IMD score*          
1 63  
(5.6%) 
68 (8.7%) 90 
 (9.3%) 
9  
(3.2%) 
15  
(6.9%) 
19  
(7.3%) 
64  
(7.5%) 
36 (10.1%) 55  
(10.4%) 
2 105 
 (9.3%) 
88 (11.2%) 104 
 (10.7%) 
26  
(9.3%) 
20 
 (9.3%) 
29 
 (11.2%) 
98 
 (11.5%) 
54 (15.2%) 72  
(13.7%) 
3 121 76 (9.7%) 116 31 30 29 100 45 (12.6%) 61 
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* IMD stands for index of multiple deprivation and is an area-based measure of socio-economic status which has been divided into quintiles, where 1 corresponds to least deprived 
and 5 to the most deprived  
  
 (10.7%)  (12%)  (11%)  (13.9%)  (11.2%)  (11.8%)  (11.6%) 
4 149 
 (13.2%) 
110 (14%) 124 
 (12.8%) 
47 
 (16.7%) 
26 
 (12%) 
38 
 (14.6%) 
120 
 (14.1%) 
47 (13.2%) 77 
 (14.6%) 
5 179  
(15.9%) 
124 (15.8%) 102 
 (10.5%) 
41 
 (14.6%) 
26 
 (12%) 
34 
 (13.1%) 
105 
 (12.4%) 
23 (6.5%) 45 
 (8.5%) 
missing 512 
 (45.4%) 
318 (40.6%) 433  
(44.7%) 
127 (45.2%) 99 
 (45.8%) 
111 
 (42.7%) 
363 
 (42.7%) 
151 (42.4%) 217 (41.2%) 
Comorbidities          
Asthma 127 
 (11.2%) 
74 (9.4%) 56 
 (5.8%) 
21 
 (7.5%) 
11 
 (5.1%) 
5  
(1.9%) 
67 
 (7.9%) 
33 (9.3%) 15  
(2.8%) 
Chronic kidney disease 
(CKD) 
103 
 (9.1%) 
62 (7.9%) 41 
 (4.2%) 
12 
 (4.3%) 
8 
 (3.7%) 
9 
 (3.5%) 
85 
 (10%) 
24 (6.7%) 23 
 (4.4%) 
Chronic obstructive 
pulmonary disease (COPD) 
370  
(32.8%) 
196 (25%) 143 
 (14.7%) 
41  
(14.6%) 
27  
(12.5%) 
20  
(7.6%) 
140  
(16.5%) 
52 (14.6%) 25  
(4.7%) 
Diabetes 96 
 (8.5%) 
85 (10.9%) 30  
(3.1%)  
20 
 (7.1%) 
14 
 (6.5%) 
5  
(1.9%) 
115 
 (13.5%) 
34 (9.5%) 14  
(2.7%) 
Hypertension 263 
 (23.3%) 
171 (21.8%) 130 
 (13.4%) 
42 
 (14.9%) 
61 
 (28.2%) 
27  
(10.4%) 
223  
(26.2%) 
75 (21.1%) 78 
 (14.8%) 
Peripheral arterial disease 103 
 (9.1%) 
50 (6.4%) 40 
 (4.1%) 
14 
 (5%) 
10 
 (4.6%) 
8 
 (3.1%) 
62  
(7.3%) 
15 (4.2%) 19 
 (3.6%) 
Stroke 102  
(9%) 
49 (6.2%) 41  
(4.2%) 
6  
(2.1%) 
10  
(4.6%) 
5 
 (1.9%) 
57  
(6.7%) 
17 (4.8%) 19 (3.6%) 
Psychosis 12  
(1.1%) 
6 
 (0.8%) 
7 
 (0.7%) 
2  
(0.7%) 
2  
(0.9%) 
1  
(0.4%) 
10 
 (1.2%) 
2  
(0.6%) 
4  
(0.8%) 
Treatment             
Surgery 177  
(15.7%) 
264 (33.7%) 134  
(13.8%) 
60 
 (21.4%) 
59 
 (27.3%) 
68  
(26.2%) 
60 
 (7.1%) 
44 (12.4%) 45  
(8.5%) 
Chemotherapy 338 
 (29.9%) 
221 (28.2%) 309 
 (31.9%) 
47 
 (16.7%) 
33  
(15.3%) 
49  
(18.8%) 
113  
(13.3%) 
63 (17.7%) 76  
(14.4%) 
Radiotherapy 199 
 (17.6%) 
98 (12.5%) 173 
 (17.9%) 
75 
 (26.7%) 
46 
 (21.3%) 
63 
 (24.2%) 
33 
 (3.9%) 
7 
 (2.0%) 
22 
 (4.2%) 
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Table 2 Risk of all-cause mortality, cancer-specific mortality and death due to index cancer in quitters compared with continuing smokers with lung, 
bladder and upper aero-digestive tract cancer   
*adjusted for age, gender, SES, co-morbidity, treatment, alcohol consumption; ppts= participants; (n) = number; MI = multiple imputation 
 Ppts 
(n) 
Total 
deaths 
(n) 
All-cause 
mortality  
HR (95% CI) 
Ppts 
(n) 
Total 
deaths 
(n) 
Cancer-specific 
mortality  
HR (95% CI) 
Ppts 
(n) 
Total 
deaths 
(n) 
Death due to index 
cancer  
HR (95% CI) 
Lung cancer 
  Unadjusted – missing exposure (extra category) 2881 2016 0.71 (0.63-0.79) 1635 1025 0.73 (0.62-0.85) 1635 954 0.72 (0.61-0.85) 
  Primary model (MI model – alcohol, SES, 
exposure)* 
2881 2016 0.82 (0.74-0.92) 1635  1025 0.89 (0.76-1.04) 1635 954 0.90 (0.77-1.05) 
  Full case analysis with missing exposure as 
category* 
835 617 0.82 (0.66-1.00) 835 529 0.87 (0.70-1.10) 835  496 0.87 (0.69-1.10) 
  Full case analysis (classify missing exposure as 
continued smokers)* 
835 617 0.83 (0.69-1.00) 835 529 0.87 (0.70-1.10) 835 496 0.84 (0.68-1.04) 
Upper aero-digestive tract cancer 
  Unadjusted – missing exposure (extra category) 757 313 0.80 (0.60-1.08) 428 120 0.96 (0.61-1.51) 428 81 0.78 (0.45-1.37) 
  Primary model (MI model – alcohol, SES, 
exposure)* 
757 313 0.81 (0.58-1.14) 428 120 0.84 (0.48-1.45) 428 81 0.75 (0.42-1.34) 
  Full case analysis with missing exposure as 
category* 
233 106 0.72 (0.40-1.27) 233 71 0.88 (0.46-1.68) 233 49 0.71 (0.31-1.62) 
  Full case analysis (classify missing exposure as 
continued smokers)* 
233 106 0.71 (0.41-1.20) 233 71 0.90 (0.43-1.63) 233 49 0.66 (0.31-1.42) 
Bladder cancer 
  Unadjusted – missing exposure (extra category) 1733 571 0.91 (0.73-1.14) 1013 213 1.23 (0.86-1.74) 1013 122 1.24 (0.77-1.99) 
  Primary model (MI model – alcohol, SES, 
exposure)* 
1733 571 1.02 (0.81-1.30) 1013 213 1.23 (0.81-1.86) 1013 122 1.25 (0.71-2.20) 
  Full case analysis with missing exposure as 
category* 
559 208 1.04 (0.72-1.52) 559 128 1.14 (0.71-1.83) 559 77 0.86 (0.44-1.65) 
  Full case analysis (classify missing exposure as 
continued smokers)* 
559 208 1.00 (0.70-1.43) 559 128 1.02 (0.66-1.58) 559 77 0.76 (0.41-1.41) 
